当前位置: 首页 > 详情页

Physiological significance of R-fMRI indices: Can functional metrics differentiate structural lesions (brain tumors)?

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai Neurosurgical Clinical Center, Shanghai, China [2]CAS Key Laboratory of Behavioral Science, Institute of Psychology, Beijing, China [3]Department of Psychology, University of Chinese Academy of Sciences, Beijing, China [4]Magnetic Resonance Imaging Research Center, Institute of Psychology, Chinese Academy of Sciences, Beijing, China [5]Department of Child and Adolescent Psychiatry, NYU Langone Medical Center School of Medicine, New York, NY, USA
出处:
ISSN:

摘要:
Resting-state functional MRI (R-fMRI) research has recently entered the era of "big data", however, few studies have provided a rigorous validation of the physiological underpinnings of R-fMRI indices. Although studies have reported that various neuropsychiatric disorders exhibit abnormalities in R-fMRI measures, these "biomarkers" have not been validated in differentiating structural lesions (brain tumors) as a concept proof. We enrolled 60 patients with intracranial tumors located in the unilateral cranialcavity and 60 matched normal controls to test whether R-fMRI indices can differentiate tumors, which represents a prerequisite for adapting such indices as biomarkers for neuropsychiatric disorders. Common R-fMRI indices of tumors and their counterpart control regions, which were defined as the contralateral normal areas (for amplitude of low frequency fluctuations (ALFF), fractional ALFF (fALFF), regional homogeneity (ReHo) and degree centrality (DC)) and ipsilateral regions surrounding the tumors (for voxel-mirrored homotopic connectivity (VMHC)), were comprehensively assessed. According to robust paired t-tests with a Bonferroni correction, only VMHC (Fisher's r-to-z transformed) could successfully differentiate substantial tumors from their counterpart normal regions in patients. Furthermore, ALFF and DC were not able to differentiate tumor from normal unless Z-standardization was employed. To validate the lower power of the between-subject design compared to the within-subject design, each metric was calculated in a matched control group, and robust two-sample t-tests were used to compare the patient tumors and the normal controls at the same place. Similarly, only VMHC succeeded in differentiating significant differences between tumors and the sham tumor areas of normal controls. This study tested the premise of R-fMRI biomarkers for differentiating lesions, and brings a new understanding to physical significance of the Z-standardization. Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

语种:
PubmedID:
中科院(CAS)分区:
出版当年[2018]版:
大类 | 2 区 医学
小类 | 2 区 神经成像
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 神经成像
JCR分区:
出版当年[2017]版:
Q1 NEUROIMAGING
最新[2024]版:
Q1 NEUROIMAGING

影响因子: 最新[2024版] 最新五年平均 出版当年[2017版] 出版当年五年平均 出版前一年[2016版] 出版后一年[2018版]

第一作者:
第一作者机构: [1]Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai Neurosurgical Clinical Center, Shanghai, China
共同第一作者:
通讯作者:
通讯机构: [1]Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai Neurosurgical Clinical Center, Shanghai, China [2]CAS Key Laboratory of Behavioral Science, Institute of Psychology, Beijing, China [3]Department of Psychology, University of Chinese Academy of Sciences, Beijing, China [4]Magnetic Resonance Imaging Research Center, Institute of Psychology, Chinese Academy of Sciences, Beijing, China [5]Department of Child and Adolescent Psychiatry, NYU Langone Medical Center School of Medicine, New York, NY, USA [*1]CAS Key Laboratory of Behavioral Science, Institute of Psychology, 16 Lincui Road, Chaoyang District, Beijing 100101, China. [*2]No. 12 Mid Wulumuqi Rd, Department of Neurosurgery, Hua Shan Hospital, Fudan University, Shanghai Neurosurgery Clinical Center, Shanghai 200040, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:18261 今日访问量:1 总访问量:1004 更新日期:2025-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院